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Abstract: 
Background: Feeding intolerance is prevalent in very low birth weight 
(VLBW) neonates and is a barrier for better and faster growth in these 
neonates. Some studies have supported the administration of oral probiotic to 
decrease feeding intolerance. The aim of this study was to evaluate the effect of 
probiotic on feeding intolerance in VLBW neonates.  
Methods: This randomized clinical trial study was conducted on 60 VLBW 
neonates who were randomly divided into two equal groups. In the case group, 
the infants received probiotic in addition to routine therapy. Duration of 
hospitalization, time to reach to full enteral feeding and birth weight, the 
numbers of vomiting and defecation, c-reactive protein rising, daily weight 
gain were compared between two groups.  
Results: No significant differences were observed between two groups in 
regard with gender, birth weight, method of delivery and gestational age. Mean 
of duration of hospitalization was 42.27 and 31.6 days in control and drug 
groups, respectively and there was significant difference (P-value=0.005). 
There was no significant difference between two groups in terms of reaching 
full enteral feeding, the numbers of vomiting and defecation, time to reach to 
birth weight, CRP rising and  daily weight gain but these results were better in 
probiotic group. 
Conclusions: This study showed that prophylactic administration of probiotic 
had significant role in reducing the duration of hospitalization of VLBW 
neonates and was effective in reaching full enteral feeding. It is suggested that 
the administration of probiotic can be helpful for feeding tolerance in VLBW 
neonates.  
Keywords: Feeding Intolerance, Prevention, Oral Probiotic, , Very Low Birth 
Weight, Neonate 
 
 
 
 
 
 
 
 
Introduction: 
Feeding intolerance is a well-known phenomenon in the neonatal intensive 
care unit (NICU) and is often associated with morbidity and mortality in 
preterm infants 
[1]
. Feeding intolerance is the inability to digest enteral nutrition 
which is associated with gastric residual increase, abdominal distention with 
vomiting commonly seen in preterm infants and often leads to nutrition 
interruption 
[2]
. Feeding intolerance occurs in76.4% of VLBW neonates (under 
1500 grams) 
[3]
. Poor digestion associated with a delay in transmission can 
damage bowel as a premature host 
[4]
. Necrotizing enterocolitis (NEC) is the 
most common acquired gastrointestinal disease in preterm infants 
[5]
. There is 
not a single theory to explain the pathogenesis of necrotizing enterocolitis and 
many mechanisms have been proposed for it including the immature intestinal  
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digestion and abnormal regulated blood circulation, 
and the innate immune system and bacterial 
colonization
 [6]
. 
These factors not only can cause feeding 
intolerance, but also lead to life-threatening conditions 
such as NEC 
[7]
. Although the specific etiology of 
necrotizing enterocolitis is still under discussion, 
epidemiologic analysis determines strategic risk factors 
of immaturity, enteral nutrition, ischemia/asphyxia and 
intestinal bacterial colonization 
[8]
. Diagnosis is based 
on clinical symptoms and ruling out other diseases 
[9]
.  
Modified Bell classification includes stage I: 
suspected necrotizing enterocolitis with abdominal 
distention, bloody stools and vomiting/gastroeso-
phageal residual stage II: proven necrotizing 
enterocolitis with symptoms associated with abdominal 
tenderness±metabolic acidosis and thrombocytopenia, 
stage III: advanced necrotizing enterocolitis with 
symptoms associated with hypotension, metabolic 
acidosis, thrombocytopenia/DIC, neutropenia 
[8]
. 
Reaching to full enteral feeding can cause removing 
catheters, less sepsis, and other catheter-related 
complications 
[10]
. 
Antenatal use of glucocorticoids with preferential 
feeding with fresh breast milk, serious prevention and 
treatment of sepsis and a cautious enteral nutrition are 
required strategies to prevent necrotizing enterocolitis 
[11]
. Premature infants in the NICU have different 
intestinal microbial environment than healthy infants 
fed with breast milk. Contact with the native microbial 
environment is reduced but the exposure to organisms 
that had been colonized in the NICU increases due to 
antibiotics advising and delay in enteral feeding 
[12]
. 
Many researchers have tried to modify the 
microbial environment of the preterm infants' gut for 
being similar to full-term breastfed babies hoping that 
growth and development will be improved and the 
nosocomial episodes of infection and necrotizing 
enterocolitis will be decreased 
[13]
. Recent studies have 
investigated the use of probiotic for the prevention of 
necrotizing enterocolitis in preterm infants and 
convinced neonatologists to apply them routinely in the 
near future 
[14]
. Several proposed mechanisms include 
maintenance of mucosal barrier, preventing bacterial 
replacement, setting to bacterial colonization, enabling 
the general resistance of the body and regulating 
intestinal inflammation 
[15]
. 
Probiotic, prebiotics and symbiotic are essential to 
prevent this disease 
[16]
. Recent studies have shown that 
the administration of probiotic supplementation 
improves the feeding tolerance, time to reach full 
enteral nutrition, better weight gain, lower incidence of 
necrotizing enterocolitis and death due to necrotizing 
enterocolitis (NEC) stage is lower 
[17, 18, 19, 20, 21, 22 and 23]
. 
Most of the studies had investigated the probiotics 
effect in preventing necrotizing enterocolitis on VLBW 
neonates (under 1500 grams), but in this study, feeding 
intolerance in neonates under 1500 grams, i.e. 1000 
grams, was examined. 
In the current study, the probiotic drops containing 
three strains of bacteria (made in Iran), 1-Lactobacillus 
Rhamnosus 2- Lactobacillus Ruteri 3- Bifidobactrium 
Infantis, were used while fewer strains had been used 
in most studies. Experimental studies on animals and 
humans advocated the idea that the administration of 
probiotic reduced feeding intolerance and NEC which 
led to death in preterm neonates, but the matter is still 
controversial. This study was designed to investigate 
the feeding intolerance in neonates under 1500 grams. 
 
 
Methods: 
This clinical trial was conducted on 60 VLBW 
neonates who were randomly divided into two equal 
sizes (control and intervention group). Neonates with 
gastrointestinal obstruction, congenital heart disease, 
major congenital abnormalities, death in the first 72 
hours of life, the babies whose mothers used probiotic 
supplement and the formula-fed neonates were 
excluded from the current study. 
All patients received standard treatment, were 
breastfed and their information were confidential and 
no additional tests were not imposed on the patients. In 
addition, the written consent was taken from all parents 
before the start of treatment.  
In the intervention group with reaching feeding 
volume to 5 cc/kg/day, 3 drops as daily oral probiotic 
in neonates 1500- 1000 grams and two drops in a day 
in infants less than 1000 grams were added to mother's 
milk in every 12 hours until the enteral feeding was 
completed (160-120 cc per kilogram for body weight).  
Consumed probiotic named Pedilact manufactured 
by Zist takhmir company (Iran), which contained 3 
strains of microorganism products as follows: 
Lactobacillus reuteri (4×108 - colony forming 
unite-cfu/gtt), Lactolacillus rhamnosus (2×109 cfu/gtt( 
and Bifidobactrium Infantis (3×108 cfu/gtt( and 
pharmaceutical storage was according to company 
protocol during the study. 
In the control group, routine treatment of the 
underlying condition was done and there was no 
placebo intervention. CRP, CBC, blood cultures, 
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sodium, potassium, glucose, calcium, ABG (Arterial 
blood gas) and a chest x-ray were performed for all 
included patients at the initiation of the admission in 
NICU. Weight, time to starting of feeding, daily weight 
gain, numbers of vomiting and stool passing of patients 
were recorded. When respiratory rate was reached to 
60 breaths per minute and also respiratory distress was 
diminished, oral feeding was started and the start time 
was recorded. 
For all neonates, intravenous route was established 
and 80-100 cc per kilogram of body weight fluid were 
calculated and used. All patients were treated with 
antibiotics (ampicillin-aminoglycoside) and when the 
blood cultures were negative, the antibiotics were 
discontinued. For neonates whom their feeding reached 
5 cc/kg/day, probiotic drops in the intervention group 
was administrated daily and until the patient's feeding 
reached to 120 cc/kg/day, simultaneously, with the start 
of high-calorie milk, probiotic drops were cut in the 
intervention group. The increasing amount of daily 
milk was similar in both groups. 
This study was registered in the Iranian Registry of 
Clinical Trial (www.irct.ir) with registration number 
ID: IRCT2015111925125N1. The study was approved 
by the local Ethics Committee of Babol University of 
Medical Sciences, Iran. All patients gave informed 
written consent. Data collection was done via 
observing and recording the information in the 
questionnaire by a trained nurse in NICU. Data were 
analyzed using SPSS 21, T-test and X2 tests and 
Kaplan-Meier and Cox regression methods were also 
used in the present study and P<0.05 was considered 
significant. 
 
 
Results: 
VLBW neonates were examined in two groups. 
There was no significant difference between gender, 
birth weight, mode of delivery (vaginal delivery or C-
section) and gestational age (Table 1).  
. This study showed that probiotics had significant 
impact on reducing the duration of hospitalization (P 
Value=0.05). Also in the intervention group, time to 
oral feeding and reach to birth weight (Table 2), 
incidence of sepsis and numbers of vomiting and stool 
passing were less than the control group, but the 
difference was not statistically significant.  
No significant difference was observed between the 
two groups for NEC≥Stage II Bell, but two deaths 
occurred in the intervention group, who were less than 
1000gr and none of them had positive blood cultures. 
Moreover, one of these two dead infants had 
hyperkalemia and hyponatremia and the other one had 
NEC with CRP rising; however, mortality in both 
groups had not significant difference (0.492) (Table 3). 
One of them was intra uterine growth retarded (IUGR) 
infant, too. 
 
Table 1. Basic demographic characteristics in newborns into drug and control group
* 
Variables 
drug 
(n=30) 
control 
(n=30) 
P Value 
Sex 
Male 16 (53.3) 13 (43.3) 
0.438 
Female 14 (46.7) 17 (56.7) 
Type of delivery 
Caesarean section 25 (83.3) 21 (70) 
0.222 
Normal 5 (16.7) 9 (30) 
Birth weight (mean±SD) 1245±176 1223±206 0.667 
Gestational age (weeks) (mean±SD) 30.24±1.57 30.4±2.65 0.775 
*There was no significant difference between gender, birth weight, mode of delivery and gestational age  
 
Table 2. Outcomes of birth weight, time to full enteral feeding and duration of hospitalization in drug and control group* 
(n=60) 
Variables Group Mean (CI=95%) Median (CI=95%) 
P Value 
Range Test (10) 
Time to birth weight 
(days) 
drug 18 (14.01-21.99) 16.43 (14.22-18.64) 
0.058 
control 19 (16.70-21.30) 18.87 (15.81-21.2) 
Time to oral feeding 
(days) 
drug 10 (9.11-10.90) 10.43 (9.43-11.44) 
0.253 
control 10 (8.94-11.06) 11.23 (9.76-12.71) 
Duration of hospitalization 
(days) 
drug 30 (26.17-33.83) 31.16 (35.49-26.82) 
0.005 
control 40 (23.90-56.10) 42.77 (35.32-50.22) 
* - Done with survival analysis by Kaplan-Meier method 
- No significant difference was observed between the two groups for Time to birth weight and Time to oral 
feeding 
- Significant impact on reducing the duration of hospitalization (P Value=0.05) 
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Table 3. comparing vomiting, increasing CRP
*, 2≤NEC, daily stool numbers, daily weight gain and death in the drug and 
control groups
**
 (60 = n) 
Variables Probiotic (n=30) Control (n=30) P Value 
Vomit(Number/day) 11 (36.7) 41 (46.7) 0.432 
Increasing CRP(mg/dl) 4 (13.3) 3 (10.1) 0.500 
NEC Bell stage≥2 1 (3.3) 1 (3.3) 1.000 
Bowel movements per day (SD±mean) 2.67±0.39 2.68±0.47 0.484 
Daily weight gain(gr) (SD ± mean) 15.92±5.32 13.8±5.53 0.135 
Death 2 (6.7) 0 (0) 0.492 
* CRP(C-Reactive protein) 
** No significant difference was observed between the two groups for all data  
 
 
Discussion: 
This clinical trial evaluated the effect of probiotics 
in the prevention of feeding intolerance in VLBW 
neonates and showed that prophylactic probiotic was 
effective in reducing the duration of hospital stay and 
although it had better outcomes in other cases such as 
vomiting and increased CRP and daily stool numbers 
and daily weight gain and reaching to full enteral 
feeding and time to achieve weight birth in the 
probiotic group compared to control group, this 
difference was not significant. Though the death was 
not significant in both groups, the administration of 
probiotic would be done cautiously and carefully due 
to the mortality of two neonates under 1000 gr.  
In a study performed by Cheng Huan et al., the 
incidence of feeding intolerance, time to full enteral 
feeding and serum bilirubin level was lower and weight 
gain was faster in the treatment group. Side effects 
were not observed in the intervention group so their 
results were nearly identical to the present study. 
[17]
.  
Al-Hosni et al. showed that although the nutrition 
with probiotic improved growth of neonates less than 
1000 grams, the improvement was not observed in 
some infants with developmental delay in 34 weeks. 
Moreover, no side effects of probiotic were reported 
[18]
. The results of their study were in consistent with 
those of the current study because of different kinds of 
probiotic, probiotic prescription time and neonates less 
than 1000 grams. However, in their study, the 
incidence of NEC and death was similar to the present 
study. 
Fernandez et al. evaluated the probiotic effect on 
the prevention of necrotizing enterocolitis in neonates 
under 1500 grams and they indicated that NEC reduced 
in the study group (8% compared with 16% in the 
control group) 
[20]
 so their study was consistent with the 
present study.  
In a study performed by Yang et al, NEC≥ stage II 
and death were significantly lower in the probiotic 
group, but the risk of sepsis was not different between 
two groups and there was no difference between two 
groups in terms of weight gain and reach to enteral 
feeding 
[16]
. 
Their study showed that at least the probiotic did 
not increase sepsis and mortality while in the current 
study, the mortality was observed because the neonates 
of this study were under 1000. The similarity of these 
two studies is that the probiotic can shorten the 
duration of the hospitalization. 
The results of the present study indicated that the 
administration of prophylactic probiotic was effective 
in reducing the duration of hospitalization of VLBW 
neonates and was effective in other cases such as 
vomiting and increased CRP and daily stool numbers 
and daily weight gain and reaching to full enteral 
feeding and time to achieve weight birth, while the 
difference was not significant. Therefore, it cannot be 
concluded that the probiotic does not induce side 
effects in VLBW neonates and it must be cautiously 
prescribed for this group of neonates especially for 
ones under 1000 gr.  
Finally, it is suggested that further studies should be 
done with larger sample size and changing the 
consumed dose and the duration of administration. 
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